+Compare
PGEN
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
281.28M

PGEN Precigen Forecast, Technical & Fundamental Analysis

a biotechnology company, which engages in the research and development of synthetic biology technologies.

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for PGEN with price predictions
07:00 PM EST Dec 03, 2023

PGEN's RSI Indicator recovers from oversold territory

The RSI Indicator for PGEN moved out of oversold territory on October 30, 2023. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In of the 29 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 27, 2023. You may want to consider a long position or call options on PGEN as a result. In of 65 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PGEN just turned positive on November 16, 2023. Looking at past instances where PGEN's MACD turned positive, the stock continued to rise in of 30 cases over the following month. The odds of a continued upward trend are .

PGEN moved above its 50-day moving average on December 01, 2023 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PGEN advanced for three days, in of 172 cases, the price rose further within the following month. The odds of a continued upward trend are .

PGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 43 cases where PGEN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The 50-day moving average for PGEN moved below the 200-day moving average on November 14, 2023. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PGEN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for PGEN entered a downward trend on November 07, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.888) is normal, around the industry mean (20.669). P/E Ratio (0.000) is within average values for comparable stocks, (137.286). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (38.462) is also within normal values, averaging (329.913).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. PGEN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.3B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 5%. For the same Industry, the average monthly price growth was 27%, and the average quarterly price growth was 26%. MMIRF experienced the highest price growth at 247%, while BRRGF experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 22%. For the same stocks of the Industry, the average monthly volume growth was -9% and the average quarterly volume growth was 51%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 59
SMR Rating: 94
Profit Risk Rating: 95
Seasonality Score: 27 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

PGEN is expected to report earnings to fall 5.50% to -7 cents per share on February 29

Precigen PGEN Stock Earnings Reports
Q4'23
Est.
$-0.08
Q3'23
Est.
$-0.08
Q2'23
Beat
by $0.02
Q1'23
Missed
by $0.01
Q4'22
Missed
by $0.01
The last earnings report on November 09 showed earnings per share of -7 cents, meeting the estimate of -7 cents. With 1.01M shares outstanding, the current market capitalization sits at 281.28M.
A.I. Advisor
published General Information

General Information

a biotechnology company, which engages in the research and development of synthetic biology technologies.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
20374 Seneca Meadows Parkway
Phone
+1 301 556-9900
Employees
209
Web
http://www.precigen.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ASCRX13.440.13
+0.98%
American Century Small Company R
PSOAX22.900.20
+0.88%
JPMorgan Small Cap Value A
AUICX28.98-0.03
-0.10%
AB Equity Income C
HCACX23.40-0.06
-0.26%
Hartford Capital Appreciation C
LGCWX13.70-0.09
-0.65%
Lord Abbett Global Equity R6

PGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PGEN has been loosely correlated with MDGL. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if PGEN jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PGEN
1D Price
Change %
PGEN100%
+2.52%
MDGL - PGEN
51%
Loosely correlated
+4.16%
VERV - PGEN
50%
Loosely correlated
+1.61%
BEAM - PGEN
47%
Loosely correlated
-0.03%
NTLA - PGEN
43%
Loosely correlated
+0.16%
CRSP - PGEN
40%
Loosely correlated
+4.14%
More